Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
"Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS.
| Descriptor ID |
D000069480
|
| MeSH Number(s) |
D02.705.429.906.750 D03.383.742.680.245.500.600.750 D03.633.100.759.138.881.750 D13.570.230.329.525.500 D13.570.685.245.500.600.500 D26.310.423
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination".
- Chemicals and Drugs [D]
- Organic Chemicals [D02]
- Organophosphorus Compounds [D02.705]
- Organophosphonates [D02.705.429]
- Tenofovir [D02.705.429.906]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D02.705.429.906.750]
- Heterocyclic Compounds [D03]
- Heterocyclic Compounds, 1-Ring [D03.383]
- Pyrimidines [D03.383.742]
- Pyrimidine Nucleosides [D03.383.742.680]
- Cytidine [D03.383.742.680.245]
- Deoxycytidine [D03.383.742.680.245.500]
- Emtricitabine [D03.383.742.680.245.500.600]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D03.383.742.680.245.500.600.750]
- Heterocyclic Compounds, Fused-Ring [D03.633]
- Heterocyclic Compounds, 2-Ring [D03.633.100]
- Purines [D03.633.100.759]
- Adenine [D03.633.100.759.138]
- Tenofovir [D03.633.100.759.138.881]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D03.633.100.759.138.881.750]
- Nucleic Acids, Nucleotides, and Nucleosides [D13]
- Nucleosides [D13.570]
- Deoxyribonucleosides [D13.570.230]
- Deoxycytidine [D13.570.230.329]
- Emtricitabine [D13.570.230.329.525]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D13.570.230.329.525.500]
- Pyrimidine Nucleosides [D13.570.685]
- Cytidine [D13.570.685.245]
- Deoxycytidine [D13.570.685.245.500]
- Emtricitabine [D13.570.685.245.500.600]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D13.570.685.245.500.600.500]
- Pharmaceutical Preparations [D26]
- Drug Combinations [D26.310]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D26.310.423]
Below are MeSH descriptors whose meaning is more specific than "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination".
This graph shows the total number of publications written about "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" by people in this website by year, and whether "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" by people in Profiles.
-
Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. J Acquir Immune Defic Syndr. 2019 09 01; 82(1):34-40.
-
Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):271-279.